Immunome Appoints Phil Roberts as Chief Technical Officer
January 04 2024 - 8:00AM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the appointment of Phil Roberts as Chief
Technical Officer. Mr. Roberts has over three decades of experience
in product development, global manufacturing, and commercialization
of novel pharmaceutical products.
“Immunome is delighted to add Phil to our management team as we
advance our portfolio of immunotherapies, radioligand therapies,
and ADCs towards clinical development,” stated Clay Siegall, PhD,
President and Chief Executive Officer of Immunome. “With an
ambitious pipeline that spans multiple modalities, Phil’s technical
leadership will be fundamental in building our organization and to
the efficient development of our product candidates.”
“I am excited to join Immunome at this critical stage in the
company’s growth, and I look forward to continued expansion of the
company’s capabilities,” said Mr. Roberts. “Working with Clay and
the entire Immunome team to advance potential best-in-class or
first-in-class oncology therapies is a unique opportunity, and I
believe we will deliver real results for cancer patients.”
Before joining Immunome, Mr. Roberts was most recently a
consulting executive providing strategic and advisory support to
emerging biopharmaceutical and research service companies. Prior to
that, Mr. Roberts served as SVP, Technical Operations at Mirati
Therapeutics, where he was responsible for pharmaceutical product
development, manufacturing, and supply chain operations. While at
Mirati, Phil built the Tech Ops organization and led the CMC
development, accelerated approval and commercialization of Mirati’s
first product, Krazati® (a targeted KRAS G12C inhibitor). He has
held technical and operations management positions at Avanir,
Orexigen, Exelixis, Nektar, Pfizer, Roche and Eli Lilly and has
successfully developed and commercialized five novel pharmaceutical
products.
Mr. Roberts received his M.S. in Chemical Engineering from
Louisiana State University and a B.S. in Chemical Engineering from
Rensselaer Polytechnic Institute.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including radioligand therapies, ADCs, and
immunotherapies. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We may use words and
phrases such as “believes,” “plans,” “expects,” “will,” “assumes,”
“anticipates,” “looks forward to,” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. These forward
looking statements include, but are not limited to, statements
regarding Immunome’s expectation about the benefits that a Chief
Technical Officer will have on Immunome, the expansion and
advancement of Immunome’s pipeline; the development of Immunome’s
product candidates and Immunome’s approach and strategy related to
its pipeline; the growth of Immunome’s organization; Immunome’s
cash position; and other statements regarding management’s
intentions, plans, beliefs, expectations or forecasts for the
future. No forward-looking statement can be guaranteed, and actual
results may differ materially from those projected. Such
forward-looking statements are based on our expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to,
Immunome’s ability to grow and successfully execute on its business
plan, including advancing its current pipeline and any additionally
acquired assets into the clinic and expanding its pipeline through
its technology platforms, proprietary toolbox and strategic
transactions, if any; the ability of Immunome to identify, conduct
and complete IND-enabling studies; changes in the applicable laws
or regulations; the possibility that Immunome may be adversely
affected by other economic, business, and/or competitive factors;
the risk that regulatory approvals for Immunome’s programs and
product candidates are not obtained, are delayed or are subject to
unanticipated conditions that could adversely affect it; Immunome’s
ability to manage clinical trials or studies; the risk that
pre-clinical data may not be predictive of clinical data; the
complexity of numerous regulatory and legal requirements that
Immunome needs to comply with to operate its business; the reliance
on Immunome’s management and Board of Directors; the prior
experience and successes of the Immunome’s management team and
directors are not necessarily indicative of any future success;
uncertainties related to Immunome’s capital requirements, expected
cash runway and ability to raise additional funds; the failure to
obtain, adequately protect, maintain or enforce Immunome’s
intellectual property rights; and other risks and uncertainties
indicated from time to time described in Immunome’s Annual Report
on Form 10-K for the year ended December 31, 2022 filed with
Securities and Exchange Commission (“SEC”) on March 16, 2023,
Immunome’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023 filed with the SEC on November 9, 2023, and in
Immunome’s other filings with the SEC. Immunome cautions that the
foregoing list of factors is not exclusive and not to place undue
reliance upon any forward-looking statements which speak only as of
the date made. Moreover, Immunome operates in a very competitive
and rapidly changing environment. New risks emerge from time to
time. Except as required by law, Immunome does not undertake any
obligation to update publicly any forward-looking statements for
any reason after the date of this press release to conform these
statements to actual results or to changes in their
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240104347367/en/
Investor Contact
Max Rosett Interim Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024